---
title: "Cabbacis (OTCQB: CABI) issues shareholder letter from Chairman & CEO Joseph Pandolfino in Niagara Falls, N.Y."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274006499.md"
description: "In a recent announcement, Cabbacis (OTCQB: CABI) shared a letter from their Chairman and CEO, Joseph Pandolfino, addressed to shareholders. The letter discusses important updates and insights about the company's operations."
datetime: "2026-01-28T14:28:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274006499.md)
  - [en](https://longbridge.com/en/news/274006499.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274006499.md)
---

# Cabbacis (OTCQB: CABI) issues shareholder letter from Chairman & CEO Joseph Pandolfino in Niagara Falls, N.Y.

In a recent announcement, Cabbacis (OTCQB: CABI) shared a letter from their Chairman and CEO, Joseph Pandolfino, addressed to shareholders. The letter discusses important updates and insights about the company's operations.

### Related Stocks

- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [CABA.US](https://longbridge.com/en/quote/CABA.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [FDA issues complete response letter to Replimune’s RP1 for melanoma](https://longbridge.com/en/news/282511585.md)
- [08:00 ETLynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA](https://longbridge.com/en/news/282340368.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment]]>](https://longbridge.com/en/news/282578794.md)